石药巨石生物SYS6010启动Ⅲ期临床 适应症为经至少一线系统性治疗失败的局部晚期或转移性/复发食管鳞癌

新浪财经
Feb 12

药物临床试验登记与信息公示平台数据显示,石药集团巨石生物制药有限公司的SYS6010一项在经至少一线系统性治疗失败的局部晚期或转移性/复发食管鳞癌患者中对比SYS6010与研究者选择的单药化疗的有效性和安全性的随机、对照、开放、多中心的Ⅲ期临床研究已启动。临床试验登记号为CTR20260548,首次公示信息日期为2026-02-12。该药物剂型为注射用冻干粉针,用法用量为静脉滴注,按方案规定使用。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10